Stenocare AS (STENO) - Net Assets
Based on the latest financial reports, Stenocare AS (STENO) has net assets worth Dkr9.47 Million DKK (≈ $1.48 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr12.64 Million ≈ $1.98 Million USD) and total liabilities (Dkr3.17 Million ≈ $495.94K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STENO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr9.47 Million |
| % of Total Assets | 74.92% |
| Annual Growth Rate | -10.43% |
| 5-Year Change | -76.47% |
| 10-Year Change | N/A |
| Growth Volatility | 128.58 |
Stenocare AS - Net Assets Trend (2018–2025)
This chart illustrates how Stenocare AS's net assets have evolved over time, based on quarterly financial data. Also explore STENO asset base for the complete picture of this company's asset base.
Annual Net Assets for Stenocare AS (2018–2025)
The table below shows the annual net assets of Stenocare AS from 2018 to 2025. For live valuation and market cap data, see Stenocare AS stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr9.47 Million ≈ $1.48 Million |
+372.61% |
| 2024-12-31 | Dkr-3.47 Million ≈ $-543.48K |
-113.45% |
| 2023-12-31 | Dkr25.82 Million ≈ $4.04 Million |
+6.96% |
| 2022-12-31 | Dkr24.14 Million ≈ $3.78 Million |
-40.01% |
| 2021-12-31 | Dkr40.24 Million ≈ $6.30 Million |
-23.45% |
| 2020-12-31 | Dkr52.57 Million ≈ $8.23 Million |
+290.15% |
| 2019-12-31 | Dkr13.47 Million ≈ $2.11 Million |
-34.18% |
| 2018-12-31 | Dkr20.47 Million ≈ $3.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Stenocare AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 927704500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr6.00 Million | 63.35% |
| Common Stock | Dkr3.47 Million | 36.65% |
| Total Equity | Dkr9.47 Million | 100.00% |
Stenocare AS Competitors by Market Cap
The table below lists competitors of Stenocare AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cazaly Resources Ltd
AU:CAZ
|
$10.00 Million |
|
Merchant House International Ltd
AU:MHI
|
$10.00 Million |
|
Enjoy S.A
SN:ENJOY
|
$10.01 Million |
|
T.M.C. Industrial Public Company Limited
BK:TMC
|
$10.01 Million |
|
Pets at Home Group Plc
LSE:PETS
|
$9.99 Million |
|
KWG Group Holdings Limited
F:KOU
|
$9.99 Million |
|
Turbon AG
F:TUR
|
$9.99 Million |
|
FATFISH GROUP LTD.
F:1JU
|
$9.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stenocare AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,473,687 to 9,473,052, a change of 12,946,739.
- Net loss of 2,390,440 reduced equity.
- New share issuances of 7,888,116 increased equity.
- Other factors increased equity by 7,449,063.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-2.39 Million | -25.23% |
| Share Issuances | Dkr7.89 Million | +83.27% |
| Other Changes | Dkr7.45 Million | +78.63% |
| Total Change | Dkr- | % |
Book Value vs Market Value Analysis
This analysis compares Stenocare AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.73x to 6.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Dkr2.03 | Dkr1.48 | x |
| 2019-12-31 | Dkr1.34 | Dkr1.48 | x |
| 2020-12-31 | Dkr4.72 | Dkr1.48 | x |
| 2021-12-31 | Dkr3.33 | Dkr1.48 | x |
| 2022-12-31 | Dkr2.00 | Dkr1.48 | x |
| 2023-12-31 | Dkr1.85 | Dkr1.48 | x |
| 2024-12-31 | Dkr-0.10 | Dkr1.48 | x |
| 2025-12-31 | Dkr0.22 | Dkr1.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stenocare AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34.05%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.33x
- Recent ROE (-25.23%) is above the historical average (-27.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -16.00% | -79.05% | 0.19x | 1.06x | Dkr-5.32 Million |
| 2019 | 12.63% | 19.38% | 0.28x | 2.35x | Dkr354.96K |
| 2020 | -22.42% | -5939.17% | 0.00x | 1.07x | Dkr-17.04 Million |
| 2021 | -31.64% | -808.41% | 0.04x | 1.09x | Dkr-16.76 Million |
| 2022 | -67.53% | -363.13% | 0.11x | 1.64x | Dkr-18.72 Million |
| 2023 | -68.04% | -467.55% | 0.10x | 1.48x | Dkr-20.15 Million |
| 2024 | 0.00% | -1545.07% | 0.11x | 0.00x | Dkr-34.14 Million |
| 2025 | -25.23% | -34.05% | 0.56x | 1.33x | Dkr-3.34 Million |
Industry Comparison
This section compares Stenocare AS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $13,128,500,000
- Average return on equity (ROE) among peers: 12.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stenocare AS (STENO) | Dkr9.47 Million | -16.00% | 0.33x | $10.00 Million |
| H Lundbeck A/S (HLUN-A) | $12.78 Billion | 17.86% | 0.61x | $1.10 Billion |
| H Lundbeck A/S (HLUN-B) | $13.48 Billion | 6.34% | 0.75x | $5.28 Billion |
About Stenocare AS
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD oil products. The company was incorporated in 2017 and is based in Randers, Denmark.